Biotechnology News 17 October 2025

Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Stock Rallies on Technical Breakout Beam Therapeutics’ stock surged on Monday, Oct. 20, extending a strong upward streak. By mid-afternoon the share price hit $30.35, up 16.8% for the day Finviz. This marked BEAM’s highest price since early 2024

20 October 2025

Biotechnology·Financial News·Investment·Stock Market

Celcuity Stock Skyrockets 40% to Record High on ‘Practice-Changing’ Cancer Trial Results

Stock Soars on Positive Trial News Celcuity’s stock price skyrocketed on October 20, 2025 after the Minneapolis-based biotech reported game-changing clinical trial results. Shares jumped from around $52 to as high as $78–$81 intraday Marketbeat, an approximately 40–50% single-day leap,

20 October 2025

Biotechnology·Cancer Research·Clinical Trials·Investment News·Stock Market

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Stock Rockets on Samsung Mega-Deal and Cancer Test Breakthrough

Samsung Alliance Triggers Record Rally GRAIL’s stock price exploded after the company announced a strategic alliance with Samsung on October 16. Under the deal, Samsung C&T will invest $110 million in GRAIL and become the exclusive distributor of the Galleri multi-cancer

20 October 2025

Biotechnology·Health News·Investments·Stock Market

Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences (NASDAQ: SLS) stock has surged roughly 100% year-to-date, closing around $2.14 on Oct. 17, 2025 ts2.tech ts2.tech (versus a 52-week low of $0.77). In after-hours trading on Oct. 17 it spiked another +38%, briefly touching a new

20 October 2025

Biotechnology·Cancer Research·Financial Analysis·Investment News·Stock Market

Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

What to Know Before Markets Open on October 20, 2025 VKTX Stock Steadies After Volatile Stretch Viking’s stock has stabilized in recent sessions, trading in the mid-$30s after a roller-coaster few months. It ended Friday at $33.53 Marketbeat, roughly flat

19 October 2025

Biotechnology·Healthcare Industry·Investment Analysis·Stock Market

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

Clinical and Pipeline Progress CRISPR Therapeutics has reported a string of positive R&D updates in recent weeks. On October 10, 2025, CRSP presented preclinical results for CTX460, its SyNTase-based therapy for alpha-1 antitrypsin deficiency (AATD). The data – highlighted at

19 October 2025

Biotechnology·Healthcare Innovation·Investment Analysis·Stock Market

GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL’s logo at company headquarters. The Menlo Park biotech specializes in blood-based early cancer screening through its Galleri test Samsung Tradingview. GRAIL, Inc. is focused on early cancer detection – its mission is “to detect cancer early when it can

18 October 2025

Biotechnology·Cancer Research·Healthcare Innovation·Investment News·Stock Market

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Stock Price and Performance As of mid-October 2025, Sellas Life Sciences (NASDAQ:SLS) trades around $2.10–2.20. This is near the top of its 52-week range ($0.77 low) and about twice its price at the start of 2025 Stockanalysis Marketbeat. Trading volume

18 October 2025

Biotechnology·Investment Analysis·Pharma News·Stock Market

MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed Stock Soars 15% to 52-Week High on Psychedelic Breakthrough – What’s Next for MNMD?

Key Facts – October 18, 2025 MNMD Stock Rallies to New Highs on Heavy Volume MindMed’s stock has been on fire, vastly outperforming the broader market in recent weeks. Shares rocketed to a 52-week high of $13.09 on October 14,

18 October 2025

Biotechnology·Financial News·Investing·Stock Market

Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Key Facts – October 18, 2025 GILD Stock Price Rallies to New Heights Gilead’s stock has been on a tear in recent weeks, far outpacing the broader market. After trading in the high $110s earlier in October, GILD spiked 4.2%

18 October 2025

Biotechnology·Healthcare·Investment Analysis·Pharmaceuticals·Stock Market

MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

Stock Soars to 52-Week High on Investor Hype MindMed’s stock has been on fire in recent weeks, vastly outperforming the broader market. Shares rocketed to a 52-week high of $13.09 on October 14, closing that day at $12.58 with unusually

18 October 2025

Biotechnology·Financial News·Investing·Stock Market

Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Stock Jumps as Outlook Brightens Gilead’s share price has been on a tear in recent weeks, reaching new highs for 2025. By mid-day October 17, GILD was up about 4.7% to roughly $123 per share Benzinga. Year-to-date, the stock has

17 October 2025

Analyst Ratings·Biotechnology·Stock Market

Biotechnology News 17 October 2025 - 20 October 2025